1402709-93-6

Basic information

• Product Name: 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)-
• Synonyms: 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)-;6-chloro-7-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-2-(1,3-dimethylpyrazol-4-yl)-1H-imidazo[4,5-b]pyridine;CCT241736
• CAS NO: 1402709-93-6
• Molecular Formula: C₂₂H₂₃Cl₂N₇
• Molecular Weight: 456.37092
• Product Categories: API
• Mol File: 1402709-93-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)-(1402709-93-6)
• EPA Substance Registry System: 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)-(1402709-93-6)

Safety Data

• Hazardous Substances Data: 1402709-93-6(Hazardous Substances Data)

Usage

General Description

3H-Imidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)- is a complex chemical compound that contains a fused imidazopyridine ring system and various substituents. It has a chlorine atom at the 6th position and a piperazine group at the 7th position, along with a diMethyl-1H-pyrazol-4-yl group. 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)-, due to its structure and functional groups, may have various pharmacological activities or biological effects, and it could be used as a starting material for the synthesis of different pharmaceutical compounds or research chemicals. However, its specific properties, uses, and potential hazards would need to be further investigated through laboratory studies and testing.

Upstream product

• 662116-67-8 4,5-dichloro-3-nitropyridin-2-ylamine 
• 942948-56-3 5-chloro-4-(4-(4-chlorobenzyl)piperazin-1-yl)-3-nitropyridin-2-amine 
• 25016-12-0 1,3-dimethyl-1H-pyrazole-4-carbaldehyde 
• 23145-88-2 1-[(4-chlorophenyl)methyl]piperazine 
• 6980-08-1 4-chloro-3-nitro-2-pyridinamine 
• 19798-80-2 2-Amino-4-chloropyridine 

Relevant articles and documents

SALTS AND POLYMORPHIC FORMS OF 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPERAZIN-1-YL)-2-(1,3-DIMETHYL-1H-PYRAZOL-4-YL)-3H-IMIDAZO[4,5-B]PYRIDINE

The present invention relates to salts and polymorphic forms of Compound A (6-chloro-7-(4-(4- chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine), an inhibitor of Aurora kinase and FMS-like tyrosine kinase 3 (FLT3) activity. The present invention also relates to processes for the preparation of the salts and polymorphic forms of the compound, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Aurora kinase and/or FLT3 activity is implicated.

Optimization of imidazo[4,5- b ]pyridine-based kinase inhibitors: Identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia

Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin- 1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (27e), a potent inhibitor of Aurora kinases (Aurora-A Kd = 7.5 nM, Aurora-B K d = 48 nM), FLT3 kinase (Kd = 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd = 38 nM) and FLT3(D835Y) (Kd = 14 nM). FLT3-ITD causes constitutive FLT3 kinase activation and is detected in 20-35% of adults and 15% of children with acute myeloid leukemia (AML), conferring a poor prognosis in both age groups. In an in vivo setting, 27e strongly inhibited the growth of a FLT3-ITD-positive AML human tumor xenograft (MV4-11) following oral administration, with in vivo biomarker modulation and plasma free drug exposures consistent with dual FLT3 and Aurora kinase inhibition. Compound 27e, an orally bioavailable dual FLT3 and Aurora kinase inhibitor, was selected as a preclinical development candidate for the treatment of human malignancies, in particular AML, in adults and children.